Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity
- 11 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 9 (2), 200-213
- https://doi.org/10.1158/2326-6066.cir-20-0312
Abstract
Recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment (TME) contributes to cancer immune evasion. MDSCs express the chemokine receptor CXCR2, and inhibiting CXCR2 suppresses the recruitment of MDSCs into the tumor and the pre-metastatic niche. Here we compared the growth and metastasis of melanoma and breast cancer xenografts in mice exhibiting or not exhibiting targeted deletion of Cxcr2 in myeloid cells (CXCR2myeΔ/Δ vs. CXCR2 myeWT). Detailed analysis of leukocyte populations in peripheral blood and in tumors from CXCR2myeΔ/Δ mice revealed that loss of CXCR2 signaling in myeloid cells resulted in reduced intratumoral MDSCs and increased intratumoral CXCL11. The increase in intratumoral CXCL11 was derived in part from tumor-infiltrating B1b cells. The reduction in intratumoral MDSCs coupled with an increase in intratumoral B1b cells expressing CXCL11 resulted in enhanced infiltration and activation of effector CD8+ T cells in the TME of CXCR2myeΔ/Δ mice, accompanied by inhibition of tumor growth in CXCR2myeΔ/Δ mice compared to CXCR2myeWT littermates. Treatment of tumor-bearing mice with a CXCR2 antagonist (SX-682) also inhibited tumor growth, reduced intratumoral MDSCs, and increased intratumoral B1b cells expressing CXCL11, leading to an increase in activated CD8+ T cells in the tumor. Depletion of B220+ cells or depletion of CD8+ T cells reversed the tumor inhibitory properties in CXCR2myeΔ/Δ mice. These data revealed a mechanism by which loss of CXCR2 signaling in myeloid cells modulates antitumor immunity through decreasing MDSCs and enriching CXCL11-producing B1b cells in the TME, which in turn increases CD8+ T-cell recruitment and activation in tumors.Keywords
Other Versions
Funding Information
- NCI (R01CA34590)
- NCI (R01CA243326)
- NCI (R01CA116021)
- CCSG (P30CA06845)
- CCSG (V1R37CA233770-01)
- U.S. Department of Veterans Affairs (101BX002301)
This publication has 41 references indexed in Scilit:
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic MelanomaCancer Research, 2012
- Conditional ablation of Ikkb inhibits melanoma tumor development in miceJCI Insight, 2010
- CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrowJCI Insight, 2010
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancerNature, 2010
- Chemokines and chemokine receptors: new insights into cancer-related inflammationTrends in Molecular Medicine, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote MetastasisCancer Cell, 2008
- The Terminology Issue for Myeloid-Derived Suppressor CellsCancer Research, 2007